Original articlePhase 2 Randomized Clinical Study of a Rho Kinase Inhibitor, K-115, in Primary Open-Angle Glaucoma and Ocular Hypertension
Section snippets
Methods
A multicenter, prospective, randomized, placebo-controlled, double-masked, parallel-group comparison clinical study was conducted at 29 clinical centers in Japan. The institutional review board review was prospective and the study protocol was approved by each institutional review board (Appendix, Supplemental Material). Candidate patients for the clinical trial received complete information regarding the protocol, and written informed consent was obtained from each participant before entry to
Results
The enrollment of patients began in February 2010 and was completed in May 2010. In this phase 2 clinical trial, 232 patients with POAG or OHT were enrolled and 210 patients who fulfilled the eligibility criteria were subdivided randomly into 4 groups: 54 patients were assigned to placebo, 53 were assigned to 0.1% K-115, 54 were assigned to 0.2% K-115, and 49 were assigned to 0.4% K-115 and were subjected to the analyses on safety. A total of 7 patients were excluded from analyses because of
Discussion
In this clinical trial for the novel rho kinase inhibitor K-115, there was a dose-dependent reduction in the adjusted mean of the change in IOP. Most notably, the 0.4% concentration significantly and steadily reduced IOP in comparison with placebo in patients with POAG or OHT at each time point of the last visit. During 8 weeks of K-115 administration, a dose-dependent significant IOP reduction was found in a steady and repeated manner. Because 0.4% K-115 showed the most suitable IOP reduction,
Hidenobu Tanihara, MD, is a Professor and Chairman at the Department of Ophthalmology, Faculty of Life Science, Kumamoto University, Japan. His research interests include aqueous outflow system, molecular mechanisms related to glaucomatous optic neuropathy, neuro-protection and -regeneration, glaucoma surgery, and secondary glaucoma; and he has published more than 200 papers to peer-reviewed articles in these areas.
References (11)
Glaucoma. Lancet
(2011)- et al.
Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells
Exp Eye Res
(2006) - et al.
Racial differences in the cause-specific prevalence of blindness in east Baltimore
N Engl J Med
(1991) - et al.
Current and emerging medical therapies in the treatment of glaucoma
Expert Opin Emerg Drugs
(2011) - et al.
Effects of Rho-associated protein kinase inhibitor, Y-27632, on intraocular pressure and outflow facility
Invest Ophthalmol Vis Sci
(2001)
Cited by (0)
Hidenobu Tanihara, MD, is a Professor and Chairman at the Department of Ophthalmology, Faculty of Life Science, Kumamoto University, Japan. His research interests include aqueous outflow system, molecular mechanisms related to glaucomatous optic neuropathy, neuro-protection and -regeneration, glaucoma surgery, and secondary glaucoma; and he has published more than 200 papers to peer-reviewed articles in these areas.
Supplemental Material available AJO.com.
Haruki Abe is now affiliated with the Niigata Eye Clinic, Niigata, Japan.